Scott M Rawls Selected Research

Chemokines

1/2022	Multi-chemokine receptor antagonist RAP-103 inhibits opioid-derived respiratory depression, reduces opioid reinforcement and physical dependence, and normalizes opioid-induced dysregulation of mesolimbic chemokine receptors in rats.
1/2021	Chemokines, cytokines and substance use disorders.
1/2020	Chemokine Receptor Antagonists in Combination with Morphine as a Novel Strategy for Opioid Dose Reduction in Pain Management.
12/2018	Coadministration of Chemokine Receptor Antagonists with Morphine Potentiates Morphine's Analgesic Effect on Incisional Pain in Rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Scott M Rawls Research Topics

Disease

16	Hypothermia 01/2011 - 06/2002
7	Substance-Related Disorders (Drug Abuse) 01/2022 - 04/2008
7	Pain (Aches) 01/2022 - 05/2005
7	Hyperthermia 09/2014 - 09/2003
4	Cocaine-Related Disorders (Cocaine Addiction) 01/2022 - 08/2011
3	Inflammation (Inflammations) 03/2021 - 09/2009
2	Respiratory Insufficiency (Respiratory Failure) 01/2022 - 11/2021
2	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2020 - 01/2017
2	Neuroinflammatory Diseases 01/2017 - 01/2017
2	Central Nervous System Diseases (CNS Diseases) 03/2016 - 09/2014
2	Substance Withdrawal Syndrome (Withdrawal Symptoms) 10/2010 - 12/2006
1	Infections 03/2021
1	Spasm (Spasms) 01/2021
1	Memory Disorders (Memory Loss) 06/2020
1	Hyperalgesia 01/2020
1	Neuralgia (Stump Neuralgia) 01/2020
1	Poisoning 03/2019
1	Brain Injuries (Brain Injury) 01/2017
1	Neutropenia 04/2015
1	Multiple Sclerosis 12/2012
1	Chronic Pain 12/2011
1	Tremor (Tremors) 03/2010
1	Opioid-Related Disorders (Opiate Addiction) 03/2010

Drug/Important Bio-Agent (IBA)

10	Morphine (MS Contin)FDA LinkGeneric 01/2022 - 09/2003
9	Opioid Analgesics (Opioids)IBA 01/2022 - 05/2005
7	CannabinoidsIBA 01/2019 - 12/2005
5	Cocaine (Cocaine HCl)IBA 01/2022 - 03/2009
5	Chemokine ReceptorsIBA 01/2022 - 12/2018
4	ChemokinesIBA 01/2022 - 12/2018
4	Glutamic Acid (Glutamate)FDA Link 01/2022 - 09/2003
4	Ceftriaxone (Ceftriaxon)FDA LinkGeneric 09/2014 - 10/2008
4	NG-Nitroarginine Methyl Ester (L-NAME)IBA 01/2008 - 01/2006
4	(3R)- ((2,3- dihydro- 5- methyl- 3- ((4- morpholinyl)methyl)pyrrolo- (1,2,3- de)- 1,4- benzoxazin- 6- yl)(1- naphthalenyl))methanone (WIN 55,212)IBA 08/2007 - 06/2002
3	6-chloro-2-(1-piperazinyl)pyrazine (CPP)IBA 01/2022 - 09/2014
3	Nicotine FDA Link 01/2022 - 12/2011
3	Opioid Receptors (Opioid Receptor)IBA 01/2022 - 01/2020
3	Analgesics (Analgesic Drugs)IBA 11/2021 - 12/2018
3	Formaldehyde (Formol)FDA Link 11/2021 - 01/2019
3	Synthetic CathinoneIBA 03/2021 - 03/2019
3	Dopamine (Intropin)FDA LinkGeneric 06/2020 - 01/2020
3	Serotonin (5 Hydroxytryptamine)IBA 10/2010 - 05/2006
3	RimonabantIBA 09/2009 - 06/2002
3	Capsaicin (Zostrix)FDA Link 01/2008 - 12/2005
3	Cannabinoid Receptor AgonistsIBA 08/2007 - 12/2005
2	Pharmaceutical PreparationsIBA 11/2017 - 04/2008
2	Anti-Bacterial Agents (Antibiotics)IBA 12/2011 - 03/2010
2	kappa Opioid Receptors (kappa Opioid Receptor)IBA 01/2011 - 05/2005
2	delta Opioid Receptors (delta Opioid Receptor)IBA 01/2011 - 05/2006
2	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 09/2009 - 05/2009
2	Fluoxetine (Prozac)FDA LinkGeneric 01/2008 - 05/2006
2	N- (2- (4- (2- methoxyphenyl)- 1- piperazinyl)ethyl)- N- (2- pyridinyl)cyclohexanecarboxamideIBA 01/2008 - 05/2006
2	LY 235959IBA 01/2008 - 09/2003
2	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2008 - 09/2003
2	Nitric Oxide Synthase (NO Synthase)IBA 01/2008 - 01/2006
2	AgmatineIBA 05/2007 - 12/2006
2	mu Opioid Receptors (mu Opioid Receptor)IBA 05/2007 - 09/2003
2	Drug CombinationsIBA 11/2006 - 01/2006
2	4- (alpha- (4- allyl- 2,5- dimethyl- 1- piperazinyl)- 3- methoxybenzyl)- N,N- diethylbenzamideIBA 05/2006 - 04/2006
2	N- (3- methoxyphenyl)- 4- chlorocinnamanilideIBA 04/2006 - 12/2005
2	capsazepineIBA 04/2006 - 12/2005
2	Baclofen FDA LinkGeneric 01/2006 - 10/2004
1	D-Ala-peptide T-amideIBA 01/2022
1	RAP-103IBA 01/2022
1	Peptides (Polypeptides)IBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Ethanol (Ethyl Alcohol)IBA 01/2022
1	Glutamate Carboxypeptidase II (N-Acetylaspartylglutamate Peptidase)IBA 01/2022
1	TRPA1 Cation ChannelIBA 01/2022
1	mephedroneIBA 03/2021
1	CytokinesIBA 01/2021
1	mitragynineIBA 01/2020
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2020
1	AlkaloidsIBA 01/2020
1	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2020
1	Adrenergic Agents (Adrenergic Drugs)IBA 01/2020
1	CCR5 Receptors (CCR5 Receptor)IBA 01/2020
1	Oxycodone (Oxycontin)FDA LinkGeneric 06/2019
1	Meperidine (Pethidine)FDA LinkGeneric 06/2019
1	CarrageenanIBA 01/2019
1	plerixafor FDA Link 12/2018
1	Maraviroc FDA Link 12/2018
1	OrexinsIBA 11/2017
1	cathinoneIBA 11/2017
1	suvorexantIBA 11/2017
1	metabotropic glutamate receptor 2IBA 06/2017
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2017
1	Proteins (Proteins, Gene)FDA Link 12/2012
1	Amino Acid Transport System X-AG (Glutamate Transporter)IBA 12/2012
1	Carbolines (Beta-Carbolines)IBA 09/2012
1	Harmine (Telepathine)IBA 09/2012
1	LactamsIBA 12/2011
1	Methamphetamine (Desoxyn)FDA LinkGeneric 10/2010
1	beta-LactamsIBA 03/2010
1	Naloxone (Narcan)FDA LinkGeneric 03/2010

Therapy/Procedure

5	Analgesia 01/2022 - 12/2006
3	Drug Therapy (Chemotherapy) 01/2021 - 04/2008
2	Therapeutics 09/2014 - 10/2010
2	Induced Hypothermia 08/2007 - 06/2002
1	Transcutaneous Electric Nerve Stimulation (TENS) 03/2019
1	Intravenous Administration 03/2016